2. >>Products

Xbrane Joins Forces With Contract Manufacturer For Cimzia Biosimilar

Danish Firm AGC Biologics Will Assist Swedish Player Ahead Of Clinical Trials

 
• By Dean Rudge

Sweden’s Xbrane Biopharma has secured a manufacturing partner in its native Scandinavia, Denmark’s AGC Biologics, to help complete key steps for its proposed Xcimzane (certolizumab pegol) biosimilar to Cimzia ahead of Phase I and Phase III clinical trials.

Copenhagen, Denmark
AGC Biologics has its headquarters near Copenhagen • Source: Alamy

Xbrane Biopharma AB has moved quickly from the landmark filing of its proposed biosimilar to Lucentis (ranibizumab) in Europe, signing a manufacturing agreement with Danish contract development and manufacturing organization AGC Biologics for the Swedish firm’s Xcimzane, the “only global” biosimilar candidate to UCB’s Cimzia (certolizumab pegol) blockbuster.

Under the agreement, the companies will work together to “upscale the established Xcimzane manufacturing process,” and produce several commercial scale

More from Biosimilars

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

More from Products